NIKKEI 225
38,752.04 +515.97 (+1.35%) HANG SENG
18,420.38 -157.92 (-0.85%) CRUDE OIL
78.62 +0.14 (+0.18%) GOLD FUTURES
2,330.60 -0.60 (-0.03%) DOW
38,852.27 +176.59 (+0.46%) Bitcoin GBP
50,486.48 -580.83 (-1.14%)
Neuronetics, Inc. (STIM)
| Previous close | 3.8100 |
| Open | 3.8000 |
| Bid | 2.7600 x 200 |
| Ask | 4.5000 x 200 |
| Day's range | 3.5000 - 3.8600 |
| 52-week range | 1.0300 - 5.0700 |
| Volume | |
| Avg. volume | 163,605 |
| Market cap | 112.405M |
| Beta (5Y monthly) | 2.44 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0500 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 55,650 shares of the Company’s common stock (RSUs) to thirteen new non-executive employees. In accordance with NASDAQ Listing Rule
- GlobeNewswire
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearanceMALVERN, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is committed to supporting adolescents facing major depressive disorder (MDD). NeuroStar TMS (transcranial magnetic stim
- GlobeNewswire
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2024 financial and operating results prior to market open on Tuesday, May 7th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The confere
